Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease
Mark Y. Chan(National University Heart Centre Singapore), Christopher P. Rusconi(University of North Carolina at Chapel Hill), Mauricio G. Cohen(Santa Ana College), Ian C. Gilchrist(Dartmouth College), James Walder(University of North Carolina at Chapel Hill), Christopher K. Dyke(University of North Carolina at Chapel Hill), Neal S. Kleiman(Houston Methodist), Chiara Melloni, Robert A. Harrington(Clinical Research Institute), John H. Alexander(Ohio State University Hospital), David Vorchheimer(University of North Carolina at Chapel Hill), Richard C. Becker(Clinical Research Institute), Min Lin(University of North Carolina at Chapel Hill), N. Chronos(University of North Carolina at Chapel Hill), Steven R. Steinhubl(Sorbonne Université), Shelley K. Myles(University of North Carolina at Chapel Hill), Laura G. Aberle(University of North Carolina at Chapel Hill), Ross M. Tonkens(University of North Carolina at Chapel Hill)
Cited by 130
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k